Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. SMO Clinplus Co's annualizedNet Income for the quarter that ended in Jun. 2026 was ¥-37.7 Mil.
SMO Clinplus Co's average Total Assets over the quarter that ended in Jun. 2026 was ¥1,527.4 Mil. Therefore, SMO Clinplus Co's annualized ROA % for the quarter that ended in Jun. 2026 was -2.47%.
The historical rank and industry rank for SMO Clinplus Co's ROA % or its related term are showing as below:
SZSE:301257'
s ROA % Range Over the Past 10 Years
Min: 3.84 Med: 14.96 Max: 29
Current: 3.84
During the past 12 years, SMO Clinplus Co's highest ROA % was 29.00%. The lowest was 3.84%. And the median was 14.96%.
SZSE:301257's ROA % is ranked better than 70.28% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.605
vs SZSE:301257: 3.84
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
SMO Clinplus Co ROA % Related Terms
SMO Clinplus Co ROA % Historical Data
* Premium members only.
The historical data trend for SMO Clinplus Co's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, SMO Clinplus Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SMO Clinplus Co ROA % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SMO Clinplus Co's ROA % distribution charts can be found below:
* The bar in red indicates where SMO Clinplus Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
ROA % is displayed in the 30-year financial page.
SMO Clinplus Co (SZSE:301257) has a ROA % of -2.47% as of Jun. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on SMO Clinplus Co and its competitors. Over the past decade, SMO Clinplus Co's ROA % has ranged from 3.84 to 29.00. According to the industry distribution chart, SMO Clinplus Co ranks #63 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 29.7%.
Is SMO Clinplus Co's ROA % too high?
SMO Clinplus Co's current ROA % is -2.47%. Over the past 10 years, this metric has ranged from a low of 3.84 to a high of 29.00. Based on the distribution chart, SMO Clinplus Co ranks #63 out of 212 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, SMO Clinplus Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SMO Clinplus Co's ROA % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SMO Clinplus Co ranks #63 out of 212 companies for ROA %. This puts SMO Clinplus Co in the upper half of its industry. Historically, SMO Clinplus Co's own ROA % has ranged from 3.84 to 29.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Diagnostics & Research company?
A good ROA % depends on the Medical Diagnostics & Research industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on SMO Clinplus Co and its competitors. SMO Clinplus Co's current ROA % is -2.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SMO Clinplus Co stock overvalued right now?
Based on GuruFocus' analysis, SMO Clinplus Co (SZSE:301257) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥38.90, compared to a current price of ¥35.17 — trading 9.6% below its estimated fair value. The current ROA % is -2.47%. SMO Clinplus Co's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For SMO Clinplus Co (SZSE:301257), the current ROA % is -2.47% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SMO Clinplus Co (SZSE:301257) Overvalued in 2026?
Based on GuruFocus' analysis, SMO Clinplus Co stock appears to be undervalued.
The current stock price of ¥35.17 is trading 9.6% below its estimated GF Value™ of ¥38.90.
GuruFocus considers SMO Clinplus Co to be Modestly Undervalued.
Key valuation signals for SZSE:301257:
ROA %: -2.47%
GF Value™: ¥38.90 vs. price of ¥35.17 (9.6% below fair value)
No single metric tells the full story. See the SZSE:301257 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SMO Clinplus Co Ltd is engaged in providing SMO services to domestic and foreign pharmaceutical companies, medical device companies, and clinical research and development of some health-related products. The services provided include Preliminary model establishment, Preliminary plan preparation, Initiation of clinical trial sites, On-site implementation, and Comprehensive project management.
91GF Score
Get the complete analysis for SZSE:301257
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301257 has been successfully added to your 
